Who is sponsoring NCT00051571?

NCT00051571 is sponsored by Seagen Inc..

What condition does NCT00051571 study?

NCT00051571 studies Carcinoma, Non-Small-Cell Lung.

What drugs are being tested in NCT00051571?

Interventions: SGN-15, Docetaxel.

What is the status of NCT00051571?

NCT00051571 is currently COMPLETED.

Last reviewed 2011-10-21 · How we verify

A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma

NCT00051571 Phase 2 COMPLETED

This randomized phase II clinical trial evaluates the combination of a monoclonal antibody-based drug (SGN-15) with a chemotherapeutic agent compared to chemotherapy given alone in patients with non-small cell lung cancer that has failed at least one prior systemic therapy. The objective of the study is to determine the safety and clinical benefit, as measured by tumor response and quality of life, to the combination regimen. Monoclonal antibody therapy has been used in other types of cancer to target therapy to the tumor, thereby allowing for the chemotherapeutic agent to have a lesser effect on normal, healthy tissue.

Details

Lead sponsor	Seagen Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	60
Completion	2003-10

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

SGN-15
Docetaxel

Countries

United States